Novo's CEO Reset: Wegovy Pill Is Scaling, but 2026 Still Says This Isn't Explosive Growth

The reset improved the outlook, but not investor confidence

Guidance improved, but the upgraded 2026 outlook failed to reassure markets. The key issue was not the guidance change itself. It was whether Novo could calm the bigger fear that obesity growth was maturing too quickly and that competition was eroding its position.

US-listed ADRs slipped 6% after the reset, while the stock was already down 9.87% year to date and had fallen more than 20% over the last year. That combination suggests investors wanted more than a better forecast. They wanted proof that the longer-term growth story was intact.

Why better numbers were not enough

Novo did deliver a better quarter: 2026 adjusted sales and profit outlook were raised after Q2 adjusted operating profit beat expectations. But investors also focused on a narrow sales miss for the Wegovy pill and a trial setback for its next-generation obesity drug CagriSema. That keeps pressure on management to show Novo can compete more broadly than the current semaglutide cycle.

The guidance raise repaired the floor, not the premium

Novo's clearest new information was the improved 2026 outlook at CER. Management revised expectations from a 4% to 12% decline to a 0% to 6% decline for both adjusted sales and adjusted operating profit. That lifts the base case and suggests the core business is more stable than investors feared.

Still, this is not the same as explosive growth. It is a better floor. The market now needs evidence that Novo can defend its obesity franchise as the category gets more crowded.

Reuters noted Novo is battling to claw back lost ground on Eli Lilly in obesity. That context matters because investors are no longer asking only whether the Wegovy pill can attract early users. They are asking whether it can help Novo hold share in a market where Lilly has the stronger injectable position today.

Why the Wegovy pill matters most right now

The commercial case is straightforward. If patients move from injectables to the tablet, Novo can keep more of that spend inside its own portfolio instead of losing patients to a rival with a stronger injectable lineup. Even with some internal cannibalization, that shift could still support the broader treatment pathway.

There is also real launch momentum behind that argument. Novo said the Wegovy pill had 5 million total prescriptions in the U.S., while weekly prescriptions topped 265,000 for the week ending July 17. The company also launched in the UAE in June and in the U.K. in July, with additional launches in other markets planned. That makes the upside case more concrete, even if it does not eliminate execution risk.

The bull case and the bear case

The bull case rests on scaling evidence. According to Novo, the first million prescriptions took 11 weeks, while the most recent million prescriptions took four weeks, even with competition active. That suggests demand is still building.

The bear case is simpler: investors are still fixated on the narrow sales miss for the Wegovy pill. In a market where Lilly leads on injectables, momentum alone is not enough unless it translates into durable share gains.

What would make the reset investable?

The next real test comes when Novo reports first three-quarter results on 4 November 2026. That is the next chance for management to rebuild credibility after the market focused on the narrow sales miss for the Wegovy pill and the trial setback for CagriSema.

Novo has already raised its full-year outlook. What matters next is whether management can show the pill is scaling quickly enough to offset obesity-share concerns. A good checkpoint is whether weekly prescriptions remain at or above the 265,000 level reported for the week ending July 17. That would suggest the launch is holding up as competition intensifies.

International rollout matters too. The pill has surpassed 5 million total prescriptions in the U.S., and Novo has launched in the UAE in June and in the U.K. in July, with additional launches in other markets planned. If those launches proceed while U.S. velocity stays firm, the story moves closer to a durable recovery narrative.

What flips the trade, and what breaks it

A stronger setup would require three things:

• Faster pill velocity, not just healthy absolute volume.
• Evidence that international launches are adding momentum, not just diversifying timing.
• A clearer pipeline narrative beyond semaglutide, after the market focused on the trial setback for CagriSema.

If Novo delivers that, the reset can start to look investable. If it only repeats the same guidance cleanup without firmer commercial proof, the market is likely to keep treating this as a wait-and-see story.